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Abstract.  Cultured endothelial cells secrete a platelet- 
derived growth factor-like molecule (PDGFc). We ex- 
amined the effects of purified human ct-thrombin on the 
production of PDGFc in cultures of human umbilical 
vein endothelial cells (HUVE) using a  specific radio- 
receptor assay for PDGE Addition of physiologically 
relevant concentrations of ct-thrombin (0.1 to  10 U/ml) 
induced a time- and dose-dependent increase in the 
release of PDGFc into the culture medium.  Significant 
stimulation of PDGFc release was observed as early 
as  1.5 h after addition of tx-thrombin (10 U/ml) with 
a 4.9  +  1.1 fold increase at 24 h (mean  -1-  SEM of 
nine experiments, P  <  0.01). ~t-Thrombin treatment of 
HUVE did not affect cell viability as assessed by try- 
pan blue dye exclusion.  The receptor binding of 
PDGFc secreted by HUVE in response to ct-thrombin 
was inhibited by monospecific antibody to purified hu- 
man PDGF indicating that the molecule(s) is closely 
related to PDGE tx-Thrombin  inactivated with diisopro- 
pylfluorophosphate was without stimulatory effect. Ly- 
sis of HUVE by repeated cycles of freeze/thaw released 
minimal PDGFc (<0.3 ng per 106 cells) compared to 
levels of PDGFc released into supernatant medium in 
response to a-thrombin (>5.0 ng per 10  ~ cells after a 
24-h incubation with  10 U/ml ~t-thrombin).  Moreover, 
incubation of freeze/thaw lysates of HUVE with 0t- 
thrombin failed to release PDGFc. Over a 3-h time 
course, however, ct-thrombin-induced  secretion of 
PDGFc was not prevented by cycloheximide. We con- 
clude that ~t-thrombin induces secretion of PDGFc 
from HUVE by a nonlytic mechanism requiring the 
serine esterase activity of the enzyme. Although this 
effect does not initially require de novo protein synthe- 
sis, it does require cell-mediated conversion of PDGFc 
from an inactive to an active form. 
p 
LATELET-DERIVED growth factor (PDGF) 1 is a heat- 
stable,  cationic polypeptide with growth-promoting 
and chemoattractant  activities (28).  Cultured endo- 
thelial  cells constitutively  secrete a  molecule(s) (PDGFc) 
which is antigenically  related to PDGF and which is able to 
compete with mI-PDGF for binding  to the PDGF receptor 
(8). Although it has been shown that synthesis and secretion 
of PDGFc is increased in lethally  injured endothelial  cells 
(10), factors modulating the release of PDGFc by intact, via- 
ble  endothelium  are  unknown,  a-Thrombin  is  a  multi- 
functional  enzyme with diverse effects on endothelial  cell 
function (6, 12-14, 16-19, 21, 24, 25, 33). We show here that 
at  physiologically  relevant  concentrations  purified  human 
et-thrombin induces a time- and dose-dependent secretion of 
PDGFc  from  cultured  human  umbilical  vein  endothelial 
cells (HUVE) by a nonlytic mechanism. 
1. Abbreviations  used in this paper: DIP-thrombin, diisopropylfluorophos- 
phate-treated ct-thrombin; HPDS, human plasma-derived serum; HUVE, 
human umbilical vein endothelial cells; PDGF, platelet-derived growth fac- 
tor; PDGFc, PDGF-Iike molecule(s); RRA, radioreceptor assay. 
Materials and Methods 
Cell Culture 
HUVE were obtained by collagenase digestions of umbilical cords as previ- 
ously described (32) and maintained in RPMI-1640 medium (M.A. Bio- 
products, Walkersville, MD) containing 20% fetal bovine serum (Hyclone 
Laboratories, Sterile Systems, Inc., Logan, LIT). Passaged cells were sup- 
plemented with heparin (90 I~g/ml) and endothelial cell growth factor (50 
~tg/mi) as described by Thorton et al. (31). Endothelial cell growth factor 
was prepared from bovine hypothalamus as described by Maciag et al. (22). 
Human dermal fibroblasts were obtained from explants and subcultured in 
Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY) containing 
10% calf serum (Gibco). 
Radioreceptor Assay 
Levels of PDGFc in endothelial cell-conditioned medium and endothelial 
cell lysates were measured by radioreceptor assay (RRA) as previously de- 
scribed (4). Briefly, cultures of diploid human fibroblasts were rinsed once 
with cold PBS, incubated with 1 ml test solution in binding medium for 3 h 
at 4°C with continuous oscillatory mixing, rinsed once with cold PBS, then 
incubated with 1 ml binding medium containing 0.5 ng/ml mI-PDGF for 
1 h at 4°C with continuous oscillatory mixing. The cultures were rinsed 
three times with cold binding rinse and the cell-bound mI-PDGF was 
solubilized with 1% Triton X-100. Standard curves were obtained using pure 
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Figure L Time course and dose response of a-thrombin-induced 
release of PDGFc. (A) First passage HUVE were placed in 75-cm  2 
flasks in RPMI medium containing 20%  fetal bovine serum and 
grown to confluence. Before the experiment, the cells were washed 
twice  with serum-free RPMI  medium. The  medium  was  then 
replaced with RPMI medium containing 1%  HPDS with (e) or 
without (o) purified human a-thrombin (10 U/ml). At various in- 
tervals, the conditioned medium was decanted for determination of 
PDGFc concentration by RRA. (B) 25-cm  2 flasks of confluent first 
passage HUVE were incubated for 24 h at 370C with 2 ml of RPMI 
medium supplemented with 1% HPDS or the same medium con- 
taining varying concentrations of a-thrombin.  The  conditioned 
medium was then decanted and assayed for PDGFc by RRA in the 
presence (I) or absence (e) of 100 ttg/ml of monospecific goat 
anti-human PDGF IgG. Values represent individual flasks. 
PDGF standards (0.025-0.8 ng/ml) and 20 ng/ml pure PDGF to determine 
non-specific  binding (10-20% of total binding). In each case, three or more 
different dilutions of  the conditioned media were used to determine the level 
of the PDGF-like growth factor present in the conditioned media. Values 
obtained from dilutions falling within the reliable range of the standard 
curve were averaged to give the reported value. 
Reagents 
Highly purified human PDGF and  l:SI-labeled  PDGF  were prepared as 
previously described (3, 4, 26). The IgG fraction of monospecific goat an- 
tiserum to human PDGF was purified by sodium sulphate precipitation and 
chromatography by DEAE-Sephacel and is specific for PDGF (5, 30). 
Purified  human  a-thrombin,  and  diisopropylfluorophosphate-treated 
a-thrombin (DIP-thrombin) were generously provided by Dr. John Fenton 
II, Albany, NY (9).  The specific activity of a-thrombin was 3,425  NIH 
U/rag. The specific activity of the DIP-thrombin was 0.379 NIH U/rag. 
Pooled human plasma-derived serum (HPDS) was prepared from whole 
blood obtained by venipuncture of healthy normal donors. The whole blood 
was drawn into cold 3.8 % sodium citrate (1:10) and cell-free  plasma obtained 
by centrifugntion of whole blood at 3,100 g  at 4°C for 20 rain. Plasma- 
derived serum was prepared from cell-free plasma by recalcification with 
1 M CaCI2 (1:50),  followed by incubation at 37"C for 2 h, and centrifuga- 
tion at 25,000  g  at 4"C for 20 min. The HPDS was decanted, and then 
filtered (0.22 ltm), aliquoted, and stored at -800C until use. The concentra- 
tion of PDGF in HPDS was <0.001  ng/ml as assessed by RRA. 
Cycloheximide, heparin, and aprotinin were obtained from Sigma Chem- 
ical Co., St. Louis, MO. 
Results 
Cultured HUVE constitutively released PDGFc into super- 
natant medium during a 24-h incubation (Fig.  1 A). Addition 
of a-thrombin at  10 U/ml produced a  marked increase in 
PDGFc in  conditioned medium  (Fig.  1 A).  A  significant 
effect  of a-thrombin  on PDGFc release  was  observed as 
early as 1.5-3 h (Fig.  1 A). In nine separate experiments, the 
mean fold increase (+ SEM) in PDGFc release after a 24-h 
incubation with a-thrombin (10 U/ml) .was 4.9  +  1.1  (P < 
0.01). (a-Thrombin-induced release of  PDGFc was observed 
in passaged as well as primary HUVE (see Table  V). 
Addition of a-thrombin alone to the binding medium did 
not affect the RRA for PDGF (data not shown).  Further- 
more, addition of a-thrombin to supernatant medium after 
it was decanted from the endothelial cell monolayer did not 
produce an increase in the amount of PDGFc detected. Con- 
ditioned medium (3-h incubation) from untreated endothe- 
lial cells contained 0.24 ng of PDGFc per 10  ~ cells and 0.30 
ng per 106 cells after subsequent incubation of the decanted 
medium with a-thrombin (10 U/ml at 37°C for 3 h), whereas 
in the  same experiment the conditioned medium from a- 
thrombin-treated endothelial  cells  (10  U/ml for 3  h)  con- 
tained  1.41 ng of PDGFc per  106 cells. 
At concentrations of from 0.1 to 10 U/ml, a-thrombin-in- 
duced release of PDGFc from HUVE was dose dependent 
(Fig.  1  B).  At  these  concentrations,  a-thrombin-treated 
cells remained viable throughout the incubation with >95 % 
trypan  blue  dye  exclusion  in  both  control  and  a-throm- 
bin-treated cells. The PDGF-binding competitor detected in 
medium from HUVE treated with increasing concentrations 
of a-thrombin was antigenically related to human PDGF in 
that it was neutralized by antibodies raised against purified 
human PDGF (Fig.  1 B). The anti-human PDGF IgG does 
not neutralize PDGF in fetal  bovine serum (Table  I). 
Thrombin inactivated at the serine esterase site with di- 
isopropylfluorophosphate (DIP) did not induce an increase 
in PDGFc release even at concentrations as high as 5,000 nM. 
A 50-fold excess of DIP-thrombin did not prevent a-throm- 
bin-induced release of PDGFc (Table  II). 
In a  3-h  incubation,  the  presence  of cycloheximide (10 
~tg/ml)  did  not  prevent  a-thrombin-induced  release  of 
PDGFc (Table III), despite the fact that protein synthesis was 
Table L Species Specificity of  Antibody Neutralization of  PDGF 
No  Anti-human  Non-immune 
antibody  PDGF IgG  IgG 
ng of PDGF  ng of PDGF  ng of PDGF 
Conditioned medium from 
a-thrombin-stimulated HUVE  1.40  0.11  1.47 
0.20 ng/ml purified 
human PDGF  0.22 + 0.02  <0.02  0.21  + 0.03 
20% fetal bovine serum  0.15 -t- 0.02  0.14 + 0.04  0.13  + 0.03 
60% fetal bovine serum  0.29 + 0.11  0.28 + 0.07  0.30 + 0.04 
Samples containing conditioned medium from a-thrombin-stimulated HUVE, 0.20 ng/ml purified human PDGF, or 20% and 60% fetal bovine serum were prein- 
cubated for 1 h at 4°C with or without 256 I~g/ml anti-PDGF IgG or non-immune IgG. PDGFc activity was then determined by radioreceptor  assay. Results are 
the means +  SEM of three separate  experiments. 
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Induces Release of PDGFc 
Addition to HUVE monolayer  PDGFc  (ng per 10  ~ cells) 
Medium alone  1.02 
0.63 
a-Thrombin  9.60 
10.40 
DIP-thrombin  1.87 
1.10 
ct-Thrombin +  DIP- 
thrombin  8.30 
9.69 
25--cm  2 flasks of confluent first passage  HUVE were  incubated  for 24  h in 
RPMI medium containing 1% HPDS or the same medium containing a-throm- 
bin  (100  aM),  DIP-thrombin  (5,000  aM),  or  both  a-thrombin and  DIP- 
thrombin,  The concentration of PDGFc in the conditioned medium was deter- 
mined by RRA.  Values represent  individual flasks, 
inhibited by >95 % as assessed by trichloroacetic acid-pre- 
cipitable  3H-amino  acid  incorporation  (data  not  shown). 
The role of protein synthesis in ¢t-thrombin-induced release 
of PDGFc during incubations longer than 3 h could not be 
assessed due to the fact that concentrations of cycloheximide 
sufficient  to reduce protein synthesis  by greater than 75 % (>1 
t~g/ml) were toxic to HUVE after a 4-6 h incubation. 
Endothelial cell lysis by repeated cycles of freezing and 
thawing and sonication in the presence of protease inhibitor 
released  minimal  PDGFc  (consistently <0.3  ng  per  106 
cells). During the 3-h period in which ct-thrombin-stimu- 
lated release of PDGFc was independent of de novo protein 
synthesis, a-thrombin-treated  cells  released considerably 
more PDGFc activity than was detectable in lysates of un- 
treated cells (Table IV). Similar results were observed dur- 
ing  24-h  incubations;  levels  of  PDGFc  in  conditioned 
medium of ~t-thrombin-treated cells were consistently 5- to 
10-fold greater than levels of PDGFc in lysates of untreated 
cells. 
¢t-Thrombin-induced  secretion  of  PDGFc  by  intact 
cells was not accompanied by a significant decrease in this 
small intracellular pool as assessed by measuring the PDGFc 
content  in  lysates  of  control  and  thrombin-stimulated 
HUVE.  In three  separate  experiments,  total  intracellular 
PDGFc in lysates of a-thrombin-treated cells (10 U/ml for 
24 h) was 140, 200,  and 230%  of untreated cells. 
Addition of a-thrombin to HUVE previously disrupted by 
Table III. Cycloheximide Does Not Prevent 
a- Thrombin-induced  Release of PDGFc 
Addition to HUVE Monolayer  PDGFc  (ng per 106 cells) 
Medium alone  0.16 
0.16 
¢t-Thrombin  2.16 
2.40 
Cycloheximide  0.14 
0.25 
¢t-Thrombin and cycloheximide  2.76 
3.62 
75-cm  2 flasks of confluent first passage HUVE were incubated for 3 h at 37°C 
with RPMI medium supplemented with  1% HPDS or the same medium con- 
taming ¢t-thrombin (10 U/ml), cycioheximide (10 ~g/ml), or ~t-thrombin (10 
U/ml)  and  cycloheximide  (10  Bg/ml).  The  conditioned  medium  was then 
decanted and assayed for PDGFc by RRA. Values represent individual flasks. 
Table IV. Effect of a-Thrombin on Intracellular 
vs. Released PDGFc 
Addition to HUVE monolayer  Supernatant medium  Cell lysate 
PDGFc (ng per 106 cells) 
Medium alone  0.38  0.30 
0.32  0.05 
a-Thrombin  0.85  0.06 
1.90  0.06 
75-cm  z flasks of confluent first passage HUVE were incubated for 3 h at 37"C 
with 5 ml of RPMI medium supplemented with 1% HPDS or the same medium 
containing ct-thrombin (10 U/n-d). The conditioned medium was then decanted 
and assayed for released PDGFc by RRA. After incubation,  the cell layer of 
each flask was washed twice with cold 0.02%  EDTA in isotonic saline (Irvine 
Scientific, Santa Aria, CA).  The cell layer  was then harvested  by incubation 
at 4"C with 0.05% trypsin and 0.02% EDTA in Hanks' balanced salt solution 
(Gibco) and the cell pellet resuspended in 1.0 ml of cold RPMI medium con- 
raining 1% HPDS and aprotinin (10 mglml). An aliquot was removed for deter- 
ruination of cell  number by electronic  particle  counter.  The cells were then 
disrupted by three cycles of rapid freezing and thawing,  followed by sonica- 
tion. The cell lysate was then centrifuged and the superoatant decanted for de- 
termination  of intracellular  PDGFc  by  RRA.  Values  represent  individual 
flasks. 
repeated cycles of freezing and thawing did not produce a 
significant  increase  in  PDGFc  in  supernatant  medium, 
whereas in the same experiment incubation of intact HUVE 
with ¢t-thrombin produced a threefold increase in PDGFc in 
the supernatant medium (Table V). The recovery of purified 
PDGF added to the cell lysates was >85 %. 
Discussion 
DiCorleto and Bowen-Pope (8) reported that ,~30% of the 
mitogenic activity previously detected in endothelial cell- 
conditioned  medium  (11) represented  a  platelet-derived 
growth factor-like molecule(s) (PDGFc) that was antigeni- 
cally related to purified human PDGF and that competed 
with labeled purified human PDGF for specific binding to 
the PDGF receptor. Cultured human umbilical endothelial 
cells have also been shown to express mRNA encoding the 
[~-chain of PDGF (2, 7). The factors modulating production 
of PDGFc by cultured endothelial cells have not been well 
defined. Fox and DiCodeto showed that the synthesis and 
Table V. a-Thrombin-induced  Release 
of  PDGFc Requires Intact HUVE 
PDGFc  (ng total) 
A.  Addition to HUVE monolayer 
Medium alone  4.1 
4.7 
a-Thrombin  12.1 
13.7 
B.  Addition to HUVE lysate 
Medium alone  0.55 
ct-Thrombin  0.75 
Second passage HUVE were plated  in  150-cm  2 dishes and grown to conflu- 
ence.  Immediately before the experiment,  the dishes were washed once with 
RPMI medium. In A, cells were incubated for 24 h in 10 ml of RPMI medium 
containing  1% HPDS with or without a-thrombin (10 U/re.i). In B, cells were 
first harvested from the dishes by scraping with a robber policeman and then 
resuspended in 10 ml of RPMI medium containing 1% HPDS. The resuspended 
cells were lysed by three cycles of rapid freezing and thawing. The freeze-thaw 
lysate was then incubated for 24 h with or without a-thrombin  (10 U/ml). Con- 
ditioned  medium  from A and  B  were  assayed  for  PDGF by  RRA.  Values 
represent  individual dishes, 
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endothelial cells were lethally injured by phorbol esters or 
endotoxin (10). Using DNA hybridization, Barrett et al. (2) 
observed a large increase in c-sis transcript in proliferating, 
cultured endothelial cells compared to quiescent, confluent 
endothelium in  vivo (2).  More  recently, Jaye et  al.  (15) 
demonstrated that c-sis  transcript in cultured HUVE  de- 
creased when the monolayers organized into three-dimen- 
sional tubular structures under conditions that limited prolif- 
eration and  increased  when they  subsequently converted 
from the organized structure to a  proliferative monolayer 
(15). These observations suggest that the c-sis gene may be 
activated in endothelial cells as a  result of increased cell 
proliferation in vitro. 
a-Thrombin is a multifunctional  enzyme generated at sites 
of vascular injury. It enhances synthesis and secretion of a 
number  of  endothelial  cell  products  in  vitro  including 
prostacyclin (33), adenine nucleotides (24), von Willebrand 
factor (18, 19), plasminogen activator (17) and plasminogen 
activator-inhibitor  (14), platelet-activating  factor  (6,  25), 
fibronectin (12), and thromboplastin (13). In view of these 
diverse effects of ct-thrombin on endothelial cell function in 
vitro, we hypothesized that ~t-thrombin may be an important 
endogenous physiologic mediator of PDGFc release from 
endothelial cells. 
Our studies show that addition of ct-thrombin to cultured 
HUVE results in a marked increase in PDGFc in the medi- 
um.  A  significant increase  in  PDGFc  in the conditioned 
medium occurs as early as  1.5 h  after the addition of ~t- 
thrombin. At physiologically relevant concentrations of ~t- 
thrombin (0.1 to 10 U/ml) (29), ct-thrombin-induced release 
of PDGFc is dose dependent. In contrast to phorbol esters 
and endotoxins (10), the  release  of PDGFc  by  ct-throm- 
bin-treated HUVE is not accompanied by a decrease in ~n- 
dothelial  cell  viability.  The  binding  of molecules  from 
~t-thrombin-stimulated conditioned medium to the PDGF 
receptor is inhibited by antibody to human PDGF indicating 
that PDGFc detected in the conditioned medium is antigeni- 
cally similar to human PDGF. Since the anti-human PDGF 
antibody does not neutralize PDGF in the fetal bovine serum 
in which the HUVE are cultured (Table I), PDGFc released 
by tl-thrombin must be derived from the HUVE.  The fact 
that a-thrombin also releases PDGFc from passaged HUVE 
that have undergone many population doublings after initial 
isolation strongly suggests that PDGFc released by tz-throm- 
bin is synthesized by HUVE rather than simply taken up and 
stored by HUVE in vivo and later released in culture. 
tx-Thrombin inactivated at the serine esterase site with DIP 
does not induce an increase in PDGFc release by HUVE 
(Table II). In all studies in which it has been examined (13, 
16-19, 21, 25), the serine esterase activity of ~t-thrombin  is 
required for ~t-thrombin-mediated effects on endothelial cell 
function. Although apparently inactive biologically, DIP- 
thrombin binds to a high-affinity  binding site on HUVE with 
the same affinity as tx-thrombin (1). Moreover, excess DIP- 
thrombin inhibits the binding of ~t-thrombin  to the high- 
affinity binding sites (1). Nevertheless, a 50-fold excess of 
DIP-thromhin does not prevent ~t-thrombin induced release 
of  PDGFc  (Table  II).  ~t-Thrombin-mediated  release  of 
prostacyclin (20),  yon Willebrand factor (18, 19), and plas- 
minogen activator (17) are also unaffected by concentrations 
of DIP-thrombin that inhibit et-thrombin binding to the high- 
affinity binding sites.  It thus appears that several  important 
biologic effects of ct-thrombin on HUVE do not involve the 
high affinity, active site-independent binding sites.  It is not 
known whether tz-thrombin stimulates these responses by 
binding to an active site-dependent ~ceptor that is distinct 
from the receptor that recognizes ~tla ¢t- and DIP-thrombin 
or by proteolytically cleaving a plasma membrane substrate 
(20). 
Although the serine esterase activity of ct-thrombin is re- 
quired  for  ~t-thrombin  to, induce release  of PDGFc,  our 
results suggest that ~t-thrornbin does not simply act as a pro- 
tease to convert an inactive secreted precursor into active 
PDGFc or to liberate membrane-bound PDGFc, Addition of 
tx-thrombin  to conditioned medium from untrea~ HUVE 
does not release PDGFc indicating that a-thrombin does not 
act proteolytically on;s~reted precursor. Robbins et al. (27) 
reported that v-sis/PDGF-2 gene product in Simian sarcoma 
virus-transformed cells localizes to intracellular and plasma 
membranes. In our studies, prior disruption of HUVE by 
repeated  cycles of freezing  and  thawing  prevents  subse- 
quent a-thrombin,mediated release of PDGFc (Table  V). 
This apparent requirement for an intact, viable cell argues 
against a-thrombin proteolytically releasing PDGFc from 
cell membranes. If this were the case, addition of a-throm- 
bin to the freeze-thaw lysate containing membrane fragments 
would also be expected to release PDGFc. 
ct-Thrombin-induced rlease of PDGFc is not dependent 
on de novo protein synthesis (at least during the first three 
hours) (Table HI). Release of von Willebrand factor (18, 19) 
and fibronectin (12) by ~t-thrombin-stimulated HUVE is also 
protein synthesis independent. For yon Willebrand factor it 
has been proposed that there is a pre-formed storage pool that 
is mobilized in response to ~t-thrombin (18, 19). Our studies, 
however,  indicate that  HUVE  do  not  contain  significant 
stores of pre-formed, active PDGFc (Table IV). What then 
is the source of ~t-thrombin-released PDGFc,  if it is not 
present in pre-formed stores, and if it is not newly synthe- 
sized? We postulate that HUVE contain stores of molecules 
that are not recognized by the PDGF receptor. In response 
to ct-thrombin, these molecules are converted to PDGFc and 
then released. Whether PDGFc that is released early after 
~t-thrombin  stimulation  is  derived  from  an  intracellular 
precursor (23) or from PDGFc complexed to an intracellular 
binding protein (30) remains to be determined. 
In view of  the potent mitogenic and chemoattractant activi- 
ties of PDGF,  we speculate that PDGFc released by en- 
dothelial cells in response to ct-thrombin generated at sites 
of vascular injury may play a role in inflammation, wound 
healing, and atherogenesis. In these situations, endothelial- 
derived PDGFc could serve as a longer term supplement to 
growth factors released by platelets that adhere and degranu- 
late during the initial (transient) phase of vascular trauma. 
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